이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Viracta Therapeutics 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mark Rothera

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	40.5%
CEO 임기	2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	3.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Mark Rothera 의 보수는 Viracta Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$1m	US$590k	-US$51m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$6m	US$167k	-US$49m

보상 대 시장: Mark 의 총 보상 ($USD 1.46M )은 German 시장( $USD 434.78K ).

보상과 수익: Mark 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mark Rothera (61 yo)

2yrs

테뉴어

US$1,456,596

보상

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Rothera	CEO, President & Director	2yrs	US$1.46m	데이터 없음
Darrel Cohen	Chief Medical Officer	1.1yrs	US$1.05m	0% $ 0
Susan Perrine	Scientific Founder and Consultant	13.8yrs	데이터 없음	데이터 없음
Ronald Berenson	Co-Founder and Consultant	13.8yrs	데이터 없음	데이터 없음
George Hillman	Co-Founder	no data	데이터 없음	데이터 없음
Thalia Papayannopoulou	Co-Founder	no data	데이터 없음	데이터 없음
Robert Williams	Co-Founder	no data	데이터 없음	데이터 없음
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Faerm	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Ayman El-Guindy	Chief Scientific Officer	3.2yrs	데이터 없음	데이터 없음
Cheryl Madsen	Senior Vice President of Regulatory Affairs	3.5yrs	데이터 없음	데이터 없음
Patric Nelson	Senior Vice President of Business Development & Corporate Strategy	3.2yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: RYI 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Rothera	CEO, President & Director	2yrs	US$1.46m	데이터 없음
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ivor Royston	Director	3.6yrs	US$90.76k	2.11% $ 164.5k
Thomas Darcy	Independent Director	3.6yrs	US$113.26k	0% $ 0
Ronald Levy	Member of Scientific Advisory Board	6yrs	데이터 없음	데이터 없음
Carl June	Member of Scientific Advisory Board	6yrs	데이터 없음	데이터 없음
Barry Simon	Independent Director	3.5yrs	US$110.76k	0% $ 0
Roger Pomerantz	Independent Chairman of the Board	3.6yrs	US$210.27k	0.30% $ 23.2k
Lawrence Young	Member of Scientific Advisory Board	6yrs	데이터 없음	데이터 없음
Robert Baiocchi	Member of Scientific Advisory Board	6yrs	데이터 없음	데이터 없음
Pierluigi Porcu	Member of Scientific Advisory Board	6yrs	데이터 없음	데이터 없음
Stephen Rubino	Independent Director	3.5yrs	US$108.26k	0% $ 0

3.6yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: RYI 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Viracta Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

High number of new directors

High number of new directors

Recent updates

New major risk - Market cap size

New minor risk - Shareholder dilution

New major risk - Financial position

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

New major risk - Revenue and earnings growth

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics, Inc. Announces Executive Changes

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령